RespireRx Pharmaceuticals Inc. to Present at the Jefferies 2016
Healthcare Conference
GLEN ROCK, NJ-(Marketwired - Jun 8, 2016) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in the development of medicines for respiratory disorders,
including sleep apneas and drug-induced respiratory depression,
announced that the Company's President, CEO and Vice Chairman of
the Board of Directors, James S. Manuso, Ph.D., will present at the
Jefferies 2016 Healthcare Conference (www.jefferies.com) in New
York, New York on Friday, June 10, 2016 at 10:00 AM Eastern Time.
The Conference is sponsored by Jefferies & Company, Inc. and is
being held at The Grand Hyatt Hotel, New York, New York, from June
7 through June 10, 2016.
Commented Dr. Manuso, "The presentation at the Jefferies
Conference will update investors on RespireRx's strategic
initiatives and progress on research and development programs. I
look forward to discussing the Company's ongoing Phase 2A clinical
trial evaluating the impact of the proprietary oral ampakine,
CX-1739, on opioid-induced respiratory depression." Dr. Manuso will
also provide information on the Company's other product pipeline
candidates, including dronabinol, and the Company's development
timelines. Dr. Manuso concluded, "We look forward to further
updating shareholders and other stakeholders on the progress of
RespireRx's scientific, clinical and regulatory development
initiatives during 2016."
Dr. Manuso's presentation and accompanying slides will be
accessible live, via webcast, at
http://wsw.com/webcast/jeff97/rspi/lobby=tru. Replays will be
available one hour after the presentation at the same link. A copy
of the slide deck to be presented at the conference will be
available on RespireRx's website at www.respirerx.com, by clicking
on the investors tab and following the links. A copy of the slide
presentation to be presented at the conference will be submitted in
a filing by the Company with the U.S. Securities and Exchange
Commission in a Current Report on Form 8-K prior to the
presentation and will also be available in the investors section of
the RespireRx website.
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. is a leader in the development of
medicines for respiratory disorders, with a focus on sleep apneas
and drug-induced respiratory depression. The Company holds
exclusive licenses and owns patents and patent applications for
certain families of chemical compounds that claim the chemical
structures and their use in the treatment of a variety of
disorders, as well as claims for novel uses of known drugs.
RespireRx's pharmaceutical candidates in development are derived
from two platforms, as described below.
One platform of medicines being developed by RespireRx is a
class of proprietary compounds known as ampakines, which act to
enhance the actions of the excitatory neurotransmitter glutamate at
AMPA glutamate receptors. Several ampakines, in both oral and
injectable form, are being developed by the Company for the
treatment of a variety of breathing disorders. In clinical studies,
select ampakines have shown preliminary efficacy in central sleep
apnea and in the control of respiratory depression produced by
opioids, without altering the opioid analgesic effects. In animal
models of orphan disorders, such as Pompe Disease, spinal cord
damage and perinatal respiratory distress, it has been demonstrated
that certain ampakines improve breathing function. The Company's
compounds belong to a new class that does not display the
undesirable side effects previously reported for other
ampakines.
The other platform is the class of compounds known as
cannabinoids, including, in particular, dronabinol. Under a license
agreement with the University of Illinois, the Company has rights
to patents claiming the use of cannabinoids for the treatment of
sleep-related breathing disorders. In a double-blind,
placebo-controlled, dose-ascending Phase 2A clinical study
conducted by the Company, dronabinol produced a statistically
significant reduction in the Apnea-Hypopnea Index, the primary
therapeutic end-point, and was observed to be safe and
well-tolerated in a group of patients with Obstructive Sleep Apnea
("OSA"). The University of Illinois and three other centers have
completed the dosing of a potentially pivotal, six week,
double-blind, placebo-controlled Phase 2B clinical trial
investigating the effects of dronabinol in 120 patients with OSA.
The Company is not managing or funding this clinical trial, which
is fully funded by the National Heart, Lung and Blood Institute of
the National Institutes of Health.
Additional information about the Company and the matters
discussed herein can be obtained on the Company's web-site at
www.RespireRx.com or in the Company's filings with the U.S.
Securities and Exchange Commission at www.sec.gov.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and we intend
that such forward-looking statements be subject to the safe harbor
created thereby. These might include statements regarding the
Company's financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking
statements.
In some cases, forward-looking statements may be identified by
words including "anticipates," "believes," "intends," "estimates,"
"expects," "plans," and similar expressions include, but are not
limited to, statements regarding (i) future research plans,
expenditures and results, (ii) potential collaborative
arrangements, (iii) the potential utility of our proposed products,
and (iv) the need for, and availability of, additional
financing.
The forward-looking statements included herein are based on
current expectations that involve a number of risks and
uncertainties. These forward-looking statements are based on
assumptions regarding our business and technology, which involve
judgments with respect to, among other things, future scientific,
economic and competitive conditions, and future business decisions,
all of which are difficult or impossible to predict accurately and
many of which are beyond our control. Although we believe that the
assumptions underlying the forward-looking statements are
reasonable, actual results may differ materially from those set
forth in the forward-looking statements. In light of the
significant uncertainties inherent in the forward-looking
information included herein, the inclusion of such information
should not be regarded as a representation by us or any other
person that our objectives or plans will be achieved.
Factors that could cause or contribute to such differences
include, but are not limited to, regulatory policies or changes
thereto, available cash, research and development results,
competition from other similar businesses, and market and general
economic factors. This press release should be read in conjunction
with the condensed consolidated financial statements (unaudited)
and notes thereto included in Item 1 of the Company's Quarterly
Report on Form 10-Q and the Company's Annual Report on Form 10-K
for the fiscal year ended December 31, 2015, including the section
entitled "Item 1A. Risk Factors." The Company does not intend to
update or revise any forward-looking statements to reflect new
information, future events or otherwise.
Company Contact: Jeff Margolis Vice-President, Treasurer and
Secretary Telephone: (917) 834-7206 E-mail: jmargolis@respirerx.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024